Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Thalidomide in Advanced Melanoma
NCT00005815Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 1999
- Primary completion
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temozolomide and thalidomide in melanoma (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoints: Maximum Tolerated Dose at 10 weeks and Objective Response Rate at 10 weeks. Started Dec 1999; status: completed.
02
Drugs
temozolomidethalidomide
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00005815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005815.